Sympathetic innervation alters activation of pacemaker current (If) in rat ventricle.
Pacemaker current (If) exists in both neonatal and adult ventricles, but activates at more negative voltages in the adult. This study uses whole-cell patch clamp to investigate the factors that may contribute to the maturational shift of If, comparing neonatal rat ventricular myocytes that were cultured for 4-6 days either alone, in co-culture with sympathetic nerves, or with neurotransmitters chronically present in culture. If recorded from nerve-muscle co-cultures had a significantly more negative and shallower activation-voltage relation than that from control muscle cultures, which was reflected in the midpoint potential (V50) and slope factor (K) of activation. This effect of innervation was prevented by the sustained presence in the culture of the alpha1-adrenergic antagonist prazosin (Pz) at 10(-7) M. In parallel experiments, myocytes treated with noradrenaline (NA) at 10(-7) M or neuropeptide Y (NPY) at 10(-7) M during culture had the same If activation as control cells, but cells treated with NA and NPY together had a significantly more negative and shallower activation curve. Maximum conductance and reversal potential were unchanged. The effect of chronic exposure to NA + NPY was prevented by the sustained presence of either Pz or the NPY Y2 selective antagonist T4-[NPY(33-36)]4 (3.5 x 10(-7) M) in the culture, indicating a requirement for both alpha1-adrenergic and NPY Y2 activation. Substituting NA with the alpha1A-adrenergic selective agonist A61603 (5(-10) x 10(-9) M), in the presence of NPY, did not alter If, suggesting the involvement of alpha1B- rather than alpha1A-adrenoceptors. Further, sequential exposure to NPY followed by NA was effective in reproducing the action of chronic simultaneous exposure to these agonists, but sequential exposure to NA followed by NPY was ineffective. The results are consistent with past studies indicating that NPY affects the functional expression of the alpha1B-adrenergic cascade and suggest that sympathetic innervation induces a negative shift of If in ventricle via a combined action at alpha1B-adrenergic and NPY Y2 receptors. This effect of innervation probably contributes to the developmental maturation of If activation.
Department of Pharmacology, Columbia University, New York and Institute of Molecular Cardiology, Department of Physiology & Biophysics, SUNY at Stony Brook, NY, USA.
J
J
Qu
I S
IS
Cohen
R B
RB
Robinson
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001683:Biological Clocks / Q000502:physiology*; D002478:Cells, Cultured; D018920:Coculture Techniques; D006352:Heart Ventricles / Q000166:cytology / Q000294:innervation*; D007093:Imidazoles / Q000494:pharmacology; D016014:Linear Models; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D009474:Neurons / Q000166:cytology / Q000502:physiology*; D009478:Neuropeptide Y / Q000378:metabolism / Q000494:pharmacology; D009638:Norepinephrine / Q000378:metabolism / Q000494:pharmacology; D018408:Patch-Clamp Techniques; D011224:Prazosin / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017476:Receptors, Neuropeptide Y / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D013564:Sympathetic Nervous System / Q000502:physiology*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D016276:Ventricular Function
C094643:A 61603; D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D007093:Imidazoles; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y; D013764:Tetrahydronaphthalenes; C095889:neuropeptide Y2 receptor; D009638:Norepinephrine; D011224:Prazosin